Interest is growing rapidly across Nigeria in a new long-acting HIV prevention injection, even before its full nationwide rollout, according to health workers and community groups. The drug, Lenacapavir, is a twice-yearly injectable developed by Gilead Sciences and endorsed by the World Health Organization in 2025. It is designed to prevent HIV infection in HIV-negative individuals, offering an alternative to daily pre-exposure prophylaxis (PrEP) pills.
Nigeria has begun introducing the injection in pilot areas, with an official launch expected this week. Authorities say more than 11,000 doses have already been delivered out of a planned 52,000. Initial rollout will cover key regions including Lagos, Kano, Benue State, and the federal capital, Abuja. The drug will be provided free at designated public health facilities. Health workers report particularly high demand among high-risk groups, including serodiscordant couples, where one partner is HIV-positive. However, experts warn of widespread confusion, as some people mistakenly believe the injection can cure HIV rather than prevent it.
Nigeria remains one of the countries most affected by HIV, with an estimated two million people living with the virus. Medical professionals have welcomed the new option but stress the importance of careful rollout, regulatory oversight, and public education. Authorities note that the drug is currently approved only for HIV-negative, non-pregnant individuals. Public health advocates say that if awareness improves and access expands, the injection could significantly reduce new infections, especially among vulnerable populations.
